GPL-1 is here to stay, demand will kept growing. However at this point, i hate NVO, as it is a value trap, and i hate LLY even more, it is just too expensive. The threat of price war and patent cliff is real too. Both are just not a good entry IMO.
However, GLP-1 manufacture is not the only play.
Currently, I'm exploring companies that fix the loose skin problem with skin-tightening treatments - AIRS, INMD, APYX, ESTA, EOLS.
These few companies have been beaten down badly, as GLP-1 created the biggest headwind for clinics that do liposuction. However, they are seeing a turnaround as demand for skin-tightening treatments spikes, and it will keep growing.
Also, people are actually putting stuff back in (as crazy as it sound....) breast jobs, butt job, fat transfer to fix "Ozempic face."
Yes, these names are much more speculative, absolutely unlike NVO, which is a value play. However, I don't mind putting a small pot into some of these names, as the upside is quite high.